23,000+ patients using Philips InCourage vest therapy are living, breathing proof

A powerful pairing ​

InCourage vest therapy + RespirTech’s patient support program = improved patient outcomes​
RespirTech
InCourage is the only high frequency chest wall oscillation device that has a peer-reviewed outcomes study derived from the largest non-CF bronchiectasis registry in the world. Patients reported after 12 months with Philips InCourage vest therapy supported by the RespirTech patient support program:1,2
Hospital icon

Yearly rate of hospitalization decreased

Arrow down

61%

Lungs icon

Ability to clear lungs

Good-excellent rating increased
Arrow up

64%

Health rate icon

Respiratory health

Good-excellent rating increased
Arrow up

46%

Antibiotic icon

Antibiotic use decreased

Arrow down

13%

InCourage vest therapy helps treat symptoms of patients who have respiratory conditions, like bronchiectasisCOPDcystic fibrosis, and other pulmonary disorders that can be caused by neuromuscular or neuromotor conditions.

Why choose the Philips InCourage system for your patients?

How to prescribe InCourage vest therapy for your patients:​

 

A RespirTech sales representative in your territory would be happy to help answer any questions you may have about obtaining the Philips InCourage system for your patients.

Contact info phone icon
Call 800.793.1261 or fax prescriptions to 800.962.1611
Contact info mail icon
To request information by email, use our online inquiry form below.

Real people. Real results.
Proof isn’t just numbers, it’s people who had trouble breathing from various chronic respiratory conditions, who shared how they are now breathing better and enjoying life with help from InCourage vest therapy.

References

1. Methodology: Phone surveys at regular intervals with bronchiectasis patients using the InCourage system. Data collection began 10/01/2013. As of 05/31/2021, the total cohort was 23,213 patients; 21,049 patients completed the baseline survey; 13,303 patients in 1-month cohort; 9,569 in 6-month cohort; 7,720 in 12-month cohort

2. RespirTech's bronchiectasis patient outcomes program consists of follow-up calls at periodic intervals for up to two years to encourage HFCWO adherence and ensure the device is properly set for individual needs.

3. Milla CE, Hansen LG, Weber A, Warwick WJ. High-Frequency chest compression: effect of the third generation compression waveform. Biomed Instrum Technol 2004; 38:322-328. Note: 8 CF patient study comparing triangular vs. sine waveform technology.

4. Kempainen RR, Williams CB, Hazelwood A, Rubin BK, Milla CE. Comparison of high-frequency chest wall oscillation with differing waveforms for airway clearance in cystic fibrosis. Chest. 2007;132(4):1227-1232.

Respitech
5905 Nathan Lane North, Suite 200, Plymouth, MN 55442
©2021 Koninklijke Philips N.V. All rights reserved.

Our site can best be viewed with the latest version of Microsoft Edge, Google Chrome or Firefox.